Health Condition 1: null- 18-35 year old primigravidae scheduled to undergo lower segment cesarean section
Conditions
Interventions
Intervention1: intravenous diclofenac (Group D) group: At the end of surgery, patients in the diclofenac group will receive i/v diclofenac 75mg (Dynapar AQ, Troikaa pharmaceuticals ltd.) diluted in 5m
Subsequently, in the postoperative period, patients will receive the drug at 6 hourly intervals for a period of 24 hours
Control Intervention1: intravenous diclofenac-paracetamol combination(Group DP)
Sponsors
PGIMER
Eligibility
Inclusion criteria
Inclusion criteria: ASA I/II primigravidae scheduled to undergo LSCS by pfannensteil incision, under subarachnoid block
Exclusion criteria
Exclusion criteria: history of previous LSCS, presence of major co-existing medical illness like severe asthma, uncontrolled diabetes mellitus or hypertension, liver disease, peptic ulcer disease, GI bleeding, severe PIH, already on long term analgesics, known hypersensitivity to any of the study drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24 hour rescue analgesic (tramadol) consumptionTimepoint: 24 hour rescue analgesic (tramadol) consumption | — |
Secondary
| Measure | Time frame |
|---|---|
| summed pain intensities during the entire observation period, abdominal discomfort on rest or movement, nausea or vomittingTimepoint: 0,1,2,4,8,12 and 24 hours in postoperative period | — |
Countries
India
Contacts
Public ContactDr Nidhi Bhatia
Department of Anesthesia and Intensive Care PGIMER Chandigarh
Outcome results
None listed